PT Suparma Tbk (ISX:SPMA) EBIT: Rp167,650 Mil (TTM As of Mar. 2026)


ISX:SPMA PT Suparma Tbk ISX:SPMA
78 GF Score
Price Rp206.00
GF Value Rp239.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is PT Suparma Tbk EBIT?

PT Suparma Tbk ISX:SPMA +0.98% 78 EBIT is Rp167,650 Mil as of Mar. 2026. GuruFocus rates ISX:SPMA with a GF Score™ of 78/100 and a GF Value™ of Rp239.19 (Modestly Undervalued). The stock has 6 warning signs investors should review.

PT Suparma Tbk's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was Rp18,910 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp167,650 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Suparma Tbk's annualized ROC % for the quarter that ended in Mar. 2026 was 2.96%. PT Suparma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Suparma Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.34%.


PT Suparma Tbk  (ISX:SPMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Suparma Tbk's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=113461.608 * ( 1 - 12.43% )/( (3270475.786 + 3449193.011)/ 2 )
=99358.3301256/3359834.3985
=2.96 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3661123.776 - 192607.899 - ( 198040.091 - max(0, 777954.494 - 1557247.696+198040.091))
=3270475.786

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3755254.591 - 224203.817 - ( 81857.763 - max(0, 833066.505 - 1579255.169+81857.763))
=3449193.011

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Suparma Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=75638.268/( ( (1745550.356 + max(1160044.372, 0)) + (1810787.923 + max(1265498.705, 0)) )/ 2 )
=75638.268/( ( 2905594.728 + 3076286.628 )/ 2 )
=75638.268/2990940.678
=2.53 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(214662.551 + 1070664.405 + 69381.655) - (192607.899 + 0 + 2056.34)
=1160044.372

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(198509.505 + 1206254.812 + 87965.922) - (224203.817 + 0 + 3027.7169999999)
=1265498.705

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Suparma Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=167649.904/1359117.932
=12.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Suparma Tbk EBIT Related Terms


PT Suparma Tbk EBIT Historical Data

* Premium members only.

The historical data trend for PT Suparma Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Suparma Tbk EBIT Chart

PT Suparma Tbk Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only 408,620.97 463,862.34 272,479.36 169,361.50 176,426.20

PT Suparma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27,685.86 57,841.88 31,450.99 59,447.47 18,909.57

ISX:SPMA vs SLVM: EBIT Comparison

For the Paper & Paper Products subindustry, PT Suparma Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Suparma Tbk EV-to-EBIT vs Forest Products Industry

For the Forest Products industry and Basic Materials sector, PT Suparma Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Suparma Tbk's EV-to-EBIT falls into.


ISX:SPMA
78GF Score
PT Suparma Tbk ISX:SPMA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Suparma Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp167,650 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Rp167,650 Mil mean?
PT Suparma Tbk (ISX:SPMA) has a EBIT of Rp167,650 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Suparma Tbk.
Is PT Suparma Tbk's EBIT too high?
PT Suparma Tbk's current EBIT is Rp167,650 Mil. Overall, PT Suparma Tbk has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Suparma Tbk's EBIT compare to SLVM?
PT Suparma Tbk's EBIT of Rp167,650 Mil can be compared against companies in the Forest Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Forest Products company?
A good EBIT depends on the Forest Products industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Suparma Tbk. PT Suparma Tbk's current EBIT is Rp167,650 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Suparma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Suparma Tbk (ISX:SPMA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp239.19, compared to a current price of Rp206.00 — trading 13.9% below its estimated fair value. The current EBIT is Rp167,650 Mil. PT Suparma Tbk's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Suparma Tbk (ISX:SPMA), the current EBIT is Rp167,650 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Suparma Tbk (ISX:SPMA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Suparma Tbk stock appears to be undervalued. The current stock price of Rp206.00 is trading 13.9% below its estimated GF Value™ of Rp239.19. GuruFocus considers PT Suparma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:SPMA:

  • EBIT: Rp167,650 Mil
  • GF Value™: Rp239.19 vs. price of Rp206.00 (13.9% below fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the ISX:SPMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Suparma Tbk Business Description

Address Jalan Raya Mastrip, No. 856 Warugunung, Karangpilang, East Java, Surabaya, IDN, 60221
PT Suparma Tbk is an Indonesia-based company that manufactures paper and paper products. The group manufactured paper and paper wrapping products for the industrial and consumer sectors. The firm offers Laminated Wrapping Kraft, Samson Kraft, MG Paper, Coated Duplex Board, Bathroom Tissue, Carrier Tissue, Industrial Roll Towel, Kitchen Towel, and Other products. Geographically, the firm generates the majority of its revenue from the local market.
78GF Score

Get the complete analysis for ISX:SPMA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp206.00
Price
Rp239.19
GF Value